What changed
$SNY — BUY 📊 | 6 MONTHS THESIS
🎯 latest | Rev $3.1B | EPS $1.10 vs $1.03 🟢
💡 Consensus models low-single-digit earnings growth assuming rapid erosion from generics, but Dupixent's expanding indications and new launches can sustain high-single-digit growth, with earnings power well above $4/share; the market's discount multiple fails to reflect this resilience.
📉 Reward/risk: 2.36:1
🏢 Business Quality: 7/10 - Diversified global pharma with a strong immunology franchise (Dupixent) and expansive pipeline, offset by a looming patent cliff and moderate R&D risk.
📊 Valuation: cheap - ADR trades at 9.6x annualized Q1 EPS ($4.40), a significant discount to pharma peers at 12-15x and its own 5-year average of 13x; EV/EBITDA...
🔮 Catalyst: Next quarterly earnings report, Dupixent COPD label expansion decision, or positive pipeline readout
📊 Our read: BUY. Full analysis →
https://stockduty.xyz/s/SNY0619